5 mg tablets: primary overpressure; edema caused by congestive heart failure, pulmonary edema, hepatic edema, edema of renal origin.10 mg tablets: edema caused by congestive heart failure, pulmonary edema, edema of liver origin, edema of renal origin.
Composition:
1 tabl contains 5 mg or 10 mg of torasemide. The preparation contains lactose.
Action:
A drug from the group of loop diuretics. At low doses, the pharmacodynamic profile of the drug is similar to thiazide diuretics, taking into account the severity and duration of diuresis. At higher doses, torasemide causes rapid diuresis depending on the dose used. After oral administration, the torasemide is absorbed quickly and almost completely, reaching a maximum blood concentration after 1-2 hours. Over 99% of the drug is bound to plasma proteins. Torasemide is metabolised to three metabolites by oxidation and hydroxylation of the aromatic ring. About 80% of the administered dose is excreted unchanged and as metabolites as a result of tubular secretion. T0,5 is 3-4 hours.
Contraindications:
Hypersensitivity to torasemide, sulfonylureas or any of the other ingredients. Renal impairment with anuria. Hepatic coma and pre-coma. Hypotension. Cardiac disorders. Pregnancy and breastfeeding.
Precautions:
Before starting treatment with torasemidem, the water and electrolyte balance should be restored and the cause of the dysfunction should be resolved. During long-term treatment, regular monitoring of water and electrolyte management, Glucose, uric acid, creatinine and lipids in the blood is recommended. Close monitoring of patients with a tendency to elevated blood uric acid (hyperuricemia) and gout is recommended. Carbohydrate metabolism should be monitored in patients with latent or overt diabetes. Due to the risk of increased blood levels of the drug, patients with impaired liver function should be under special control during treatment. There is no clinical experience regarding the use of the drug in children. The product contains lactose - should not be used in patients with galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.
Pregnancy and lactation:
The drug is contraindicated during pregnancy and breastfeeding.
Side effects:
Depending on the dose and treatment time, water and electrolyte disturbances may occur, especially when using a low-sodium diet. Hypokalemia may occur, especially in low-potassium diets, accompanied by vomiting, diarrhea, the use of large amounts of laxatives, and in the case of liver dysfunction. With severe diuresis, especially at the beginning of treatment, as well as in elderly patients, symptoms of electrolyte and fluid loss may occur, such as headaches and dizziness, pressure drops, weakness, drowsiness, confusion, loss of appetite, muscle cramps (may result in necessary dose adjustment). Torasemide may cause increased levels of uric acid, Glucose and plasma lipids. Symptoms of metabolic acidosis may be exacerbated. In single cases, thrombotic complications and circulatory disorders caused by blood clotting occurred. Gastrointestinal disorders may occur, and in individual cases - pancreatitis. Dryness of the oral mucosa may occur. Patients with impaired urinary outflow may experience a sudden stop. Increases in urea and creatinine in the blood plasma may occur. Torasemide may increase the activity of some liver enzymes, e.g. GGT. There have been reports of individual cases of reductions in the number of red and white blood cells as well as platelets. In individual cases, allergic reactions such as pruritus, rash and photosensitivity may occur. There may be isolated cases of visual and auditory disturbances (tinnitus, hearing loss). Leg paresthesias have rarely been reported.
Dosage:
Orally. Adults.edema: the usual dose is 5 mg once a day. If necessary, the dose can be increased gradually to 20 mg once a day. In individual, exceptional cases, 40 mg / day was used.Primary hypertension: A usual dose of 2.5 mg once a day is used. If necessary, the dose can be increased to 5 mg once a day. The study suggests that doses greater than 5 mg per day do not lead to further lowering of blood pressure. The maximum therapeutic effect is achieved after about 12 weeks of treatment. Patients with hepatic impairment should be under special control. There is no need to adjust the dosage in elderly patients.
(C)
